Hsbc Holdings PLC Sells 6,202 Shares of iRadimed Corporation $IRMD

Hsbc Holdings PLC cut its stake in iRadimed Corporation (NASDAQ:IRMD) by 28.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,357 shares of the medical equipment provider’s stock after selling 6,202 shares during the quarter. Hsbc Holdings PLC owned about 0.12% of iRadimed worth $1,469,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Tudor Investment Corp ET AL bought a new position in iRadimed in the 3rd quarter worth about $666,000. SG Americas Securities LLC increased its position in shares of iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after buying an additional 33,072 shares during the period. Baader Bank Aktiengesellschaft bought a new stake in shares of iRadimed during the fourth quarter valued at about $595,000. Bridge City Capital LLC lifted its holdings in shares of iRadimed by 19.4% in the fourth quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock worth $6,893,000 after buying an additional 11,509 shares in the last quarter. Finally, RFG Advisory LLC purchased a new stake in shares of iRadimed in the fourth quarter worth about $1,594,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Stock Up 0.6%

iRadimed stock opened at $95.08 on Tuesday. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 51.96 and a beta of 0.90. The business has a 50-day simple moving average of $94.29 and a 200 day simple moving average of $95.82. iRadimed Corporation has a 52 week low of $56.15 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, research analysts anticipate that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Wall Street Analyst Weigh In

IRMD has been the subject of several recent analyst reports. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $120.00.

Insiders Place Their Bets

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of iRadimed stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,250 shares of company stock valued at $1,836,403 over the last quarter. Company insiders own 34.60% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.